

# CITATION REPORT

List of articles citing

## Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome

DOI: 10.1093/rheumatology/kev445  
Rheumatology, 2016, 55, 1726-35.

**Source:** <https://exaly.com/paper-pdf/65546842/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 133-48	5.3	35
28	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 74	4.9	60
27	Eficacia y seguridad de rivaroxabán en enfermedad pulmonar tromboembólica en paciente con síndrome antifosfolípido con anticoagulante lipico circulante más deficiencia de Proteína S: respecto a un reporte de caso. <i>Acta Colombiana De Cuidado Intensivo</i> , <b>2017</b> , 17, 145-149	0.1	
26	Síndrome antifosfolípido. <i>Medicine</i> , <b>2017</b> , 12, 1551-1559	0.1	
25	Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. <i>Thrombosis Research</i> , <b>2017</b> , 153, 37-39	8.2	21
24	The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , <b>2017</b> , 152, 93-97	8.2	39
23	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 833-845	2.8	1
22	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2017</b> , 76, 10-20	15.5	91
21	Alveolar Hemorrhage Associated with Rivaroxaban: A Case Series. <i>Journal of Pulmonary &amp; Respiratory Medicine</i> , <b>2017</b> , 07,	0	1
20	Rheumatology in Questions. <b>2018</b> ,		1
19	Medications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases. <b>2018</b> , 153-175		1
18	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , <b>2018</b> , 133, 108-120	10.2	6
17	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 419-426	5.3	21
16	Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 104-106	2.2	7
15	Antiphospholipid syndrome presenting as acute mesenteric venous thrombosis involving a variant inferior mesenteric vein and successful treatment with rivaroxaban. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	
14	Anticoagulation in a patient with antiphospholipid syndrome and a mechanical heart valve: a case study. <i>Blood Coagulation and Fibrinolysis</i> , <b>2018</b> , 29, 472-475	1	0
13	Near-complete recanalization of jugular vein and multiple dural sinus thromboses with warfarin in a case of antiphospholipid syndrome. <i>Reumatologia</i> , <b>2018</b> , 56, 406-408	1.7	2

12	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , <b>2018</b> , 169, 35-40	8.2	22
11	Direct Oral Anticoagulants in Patients Affected by Major Congenital Thrombophilia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019044	3.2	14
10	Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , <b>2019</b> , 5, 190-200	1.3	
9	Oral Anticoagulant Therapy-When Art Meets Science. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	6
8	Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment. <i>Reumatología Clínica</i> , <b>2020</b> , 16, 71-86	0.9	4
7	Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. <i>Lupus</i> , <b>2020</b> , 29, 37-44	2.6	19
6	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. <i>Reumatología Clínica (English Edition)</i> , <b>2020</b> , 16, 71-86	0.1	
5	Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report. <i>BMJ Case Reports</i> , <b>2020</b> , 13,	0.9	1
4	Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <i>Advances in Rheumatology</i> , <b>2020</b> , 60, 29	3	3
3	[Libman-Sacks endocarditis under apixaban in a patient with a high-risk profile venous antiphospholipid syndrome]. <i>Revue De Medecine Interne</i> , <b>2021</b> , 42, 218-222	0.1	0
2	miR-19b-3p and miR-20a-5p are associated with the levels of antiphospholipid antibodies in patients with antiphospholipid syndrome. <i>Rheumatology International</i> , <b>2021</b> , 41, 1329-1335	3.6	0
1	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. <i>European Journal of Rheumatology</i> , <b>2018</b> , 5, 92-95	1.7	8